Drug Guidance for Subsidy 06/02/2026 Eplontersen and vutrisiran for hereditary transthyretin amyloidosis with polyneuropathy NRThe Ministry of Health’s Drug Advisory Committee has not recommended eplontersen or vutrisir... See all × 06/02/2026 Eplontersen and vutrisiran for hereditary transthyretin amyloidosis with polyneuropathy NRThe Ministry of Health’s Drug Advisory Committee has not recommended eplontersen or vutrisiran for inclusion on the MOH List of Subsidised Drugs for treating stage 1 or 2 hereditary transthyretin amyloidosis with polyneuropathy. The decision was based on unfavourable cost effectiveness at the prices proposed by the companies.
SUBCUTANEOUS Select a brand starting with the letter: W WAINUA SOLUTION FOR INJECTION IN AUTOINJECTOR 45MG/0.8ML [SIN17311P]